Xenofon Baraliakos takes us through SURPASS, a phase 3b head-to-head trial that demonstrated equivalence of secukinumab versus adalimumab biosimilar in patients with radiographic axial spondyloarthritis.

Researchers have found that secukinumab performs equally well to adalimumab biosimilar for the treatment of radiographic axial spondyloarthritis in a head-to-head trial.

Bisoendial Abstract Introduction The adalimumab biosimilar (ADAbio) Amgevita® has a similar efficacy and safety profile as the adalimumab reference (ADA) Humira®.

Findings from the MIRACLE study indicate that patients with rheumatoid arthritis and inadequate response to methotrexate who receive a reduced dose of methotrexate at adalimumab initiation have comparable remission outcomes to those given the maximum tolerable dose, and may have fewer adverse events.

medwireNews : The US FDA has approved adalimumab-adbm as the first interchangeable biosimilar drug to treat inflammatory arthritis and certain other immune-mediated diseases.

medwireNews : The EMA’s Committee for Medicinal Products for Human Use has recommended approval of two adalimumab biosimilars for the treatment of various rheumatic diseases.

Methods AMPLE was a phase IIIb, 2-year, randomized, head-to-head trial of abatacept versus adalimumab.

This analysis evaluated the comparative risk–benefit of UPA versus adalimumab (ADA).

The adalimumab biosimilars GP2107 and SB5 may differ in their rates of discontinuation and remission in routine clinical practice, researchers report.

UK researchers have identified a pretreatment transcriptome signature that may be associated with a DAS28 response to adalimumab in people with rheumatoid arthritis.

medwireNews : The EMA’s Committee for Medicinal Products for Human Use has recommended a new adalimumab biosimilar for approval in Europe.

Women with psoriatic arthritis may gain greater improvement in disease outcomes with secukinumab than with adalimumab, a post-hoc analysis of the EXCEED trial shows.

medwireNews : The US FDA has approved another adalimumab biosimilar – adalimumab-fkjp – for the treatment of various rheumatic diseases.

Follow-up results from the SPIRIT-H2H trial indicate that ixekizumab continues to improve joint and skin symptoms relative to adalimumab after 1 year of treatment among patients with psoriatic arthritis.

Tapering of adalimumab may be possible for some patients with rheumatoid arthritis in sustained remission, but additional research is needed to predict which groups are most suitable for this approach, phase 4 study findings indicate.

Findings from the head-to-head EXCEED trial indicate that biologic-naïve patients with psoriatic arthritis treated with secukinumab monotherapy do not experience greater musculoskeletal benefits than those given adalimumab.  Additional commentaries provided by study investigator Frank Behrens and Laura Coates.

Findings from the head-to-head EXCEED trial indicate that biologic-naïve patients with psoriatic arthritis treated with secukinumab monotherapy do not experience greater musculoskeletal benefits than those given adalimumab.

Introducing adalimumab results in better outcomes than methotrexate dose escalation among patients with psoriatic arthritis and an inadequate response to initial methotrexate therapy, suggest findings from the CONTROL trial.

Findings from the head-to-head EXCEED trial indicate that biologic-naïve patients with psoriatic arthritis treated with secukinumab monotherapy do not experience greater musculoskeletal benefits than those given adalimumab.

medwireNews : The EMA’s Committee for Medicinal Products for Human Use has recommended a new adalimumab biosimilar for approval in Europe.